Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $50.4 million.

  • Praxis Precision Medicines' Cash from Investing Activities rose 170.88% to $50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 10266.17%. This contributed to the annual value of -$248.5 million for FY2024, which is 73798.2% down from last year.
  • As of Q3 2025, Praxis Precision Medicines' Cash from Investing Activities stood at $50.4 million, which was up 170.88% from $17.9 million recorded in Q2 2025.
  • Over the past 5 years, Praxis Precision Medicines' Cash from Investing Activities peaked at $50.4 million during Q3 2025, and registered a low of -$195.9 million during Q2 2024.
  • In the last 4 years, Praxis Precision Medicines' Cash from Investing Activities had a median value of $11.4 million in 2023 and averaged -$6.8 million.
  • As far as peak fluctuations go, Praxis Precision Medicines' Cash from Investing Activities soared by 49766.08% in 2023, and later crashed by 2173600.0% in 2024.
  • Over the past 4 years, Praxis Precision Medicines' Cash from Investing Activities (Quarter) stood at $22.6 million in 2022, then tumbled by 100.22% to -$50000.0 in 2023, then tumbled by 21736.0% to -$10.9 million in 2024, then soared by 561.74% to $50.4 million in 2025.
  • Its Cash from Investing Activities was $50.4 million in Q3 2025, compared to $17.9 million in Q2 2025 and -$51.1 million in Q1 2025.